Pharmaceutical manufacturers Viatris and Innovata have sought leave to appeal last month's High Court ARV tender ruling, which set aside their contracts to supply the state's main HIV treatment. The contracts cover pills combining tenofovir, lamivudine and dolutegravir (TLD), taken by most South African patients on antiretroviral therapy.
In a judgment handed down on 20 October, acting judge Graham Girdwood upheld an application by Cipla Medpro. He found that Viatris and Innovata should have been disqualified because their manufacturing licences had expired when the bid window closed.
Continue reading with a Health Matters subscription
Subscribers read every article in full, receive the daily briefing and have access to the complete archive.
Not ready to subscribe? Get Health Matters Weekly free: the week’s top healthcare headlines every Friday.